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Sang Won Seo1,2,11,12 & Joon-Kyung Seong5,6
To develop a new method for measuring Alzheimer’s disease (AD)-specific similarity of cortical 
atrophy patterns at the individual-level, we employed an individual-level machine learning algorithm. 
A total of 869 cognitively normal (CN) individuals and 473 patients with probable AD dementia 
who underwent high-resolution 3T brain MRI were included. We propose a machine learning-based 
method for measuring the similarity of an individual subject’s cortical atrophy pattern with that of a 
representative AD patient cohort. In addition, we validated this similarity measure in two longitudinal 
cohorts consisting of 79 patients with amnestic-mild cognitive impairment (aMCI) and 27 patients with 
probable AD dementia. Surface-based morphometry classifier for discriminating AD from CN showed 
sensitivity and specificity values of 87.1% and 93.3%, respectively. In the longitudinal validation study, 
aMCI-converts had higher atrophy similarity at both baseline (p < 0.001) and first year visits (p < 0.001) 
relative to non-converters. Similarly, AD patients with faster decline had higher atrophy similarity than 
slower decliners at baseline (p = 0.042), first year (p = 0.028), and third year visits (p = 0.027). The AD-
specific atrophy similarity measure is a novel approach for the prediction of dementia risk and for the 
evaluation of AD trajectories on an individual subject level.
Alzheimer’s disease (AD) dementia is the most common form of dementia1. Previous neuroimaging studies have 
shown that patients with AD demonstrate characteristic patterns of cortical atrophy at a group-level, especially 
in the medial temporal, temporoparietal, posterior cingulate, and precuneus regions2,3. Recent classification 
methods also provide a general framework to classify individual subjects, for example using arbitrary features 
defined on a three-dimensional (3D) cortical surface4–7 or volumetric features8–10. These classification methods 
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have demonstrated adequate performance in an individual subject analysis with high accuracy. Both group- and 
individual-level analyses have successfully demonstrated the discriminating power of cortical atrophy patterns 
for AD diagnosis.
Amnestic mild cognitive impairment (aMCI) refers to a transitional state between normal cognition and 
dementia. Previous studies have found that individuals with aMCI progress to AD at a rate of approximately 
5–25% per year11,12, while about 16–23% per year reverted from aMCI to normal cognition13–15. Therefore, it is 
crucial to develop prediction criteria that can distinguish individuals with aMCI at imminent risk of conversion 
to AD dementia from those who will remain stable16. In addition, different rates of progression have also been 
observed among patients with AD6,17,18. The rate of disease progression has important implications in clinical 
practice, as it has been shown to be an important factor in determining the prognosis of AD19. To date, there have 
been various neuroimaging studies for predicting AD prognosis at the individual-level20–24. However, these were 
limited by relatively small sample sizes, and the use of less sophisticated imaging methods such as low-field mag-
netic resonance imaging (MRI). In addition, although several lines of research attempted to predict conversion to 
AD in aMCI patients, these studies presented problems related to limited prediction accuracy23–26.
In this study, we first aimed to develop a new method for measuring AD-specific similarity of cortical atrophy 
patterns at the individual-level by employing an individual-level machine learning algorithm, and then to demon-
strate the potential of this similarity measure in predicting the individual-level prognosis on the AD continuum. 
Our machine learning method, as previously demonstrated4, presents an individual subject classification based 
on incremental learning for AD diagnosis and prediction for the progression of AD using cortical thickness data. 
We adopt this method for training the group-level classifier, and then propose a new similarity measure for an 
individual-level cortical atrophy pattern compared to that of the representative AD patient. This AD-specific 
atrophy similarity measure represents how similar the cortical atrophy pattern of an individual subject is to that 
of a representative AD patient defined using a well-defined AD cohort. Specifically, we demonstrated the efficacy 
of the proposed measure using a large neuroimaging cohort of 869 cognitively normal (CN) individuals and 
473 patients with probable AD dementia. We further validated the AD-specific similarity measure using a lon-
gitudinal neuroimaging cohort, by comparing this measure between aMCI converters and non-converters and 
between AD patients with fast and slow degrees of clinical decline. We hypothesize that the proposed individual 
assessment method is useful not only for determining diagnosis of an individual subject at a given time, but also 
to predict how likely their future including both progression to AD (a one-year aMCI follow-up validation) and 
a prognosis of AD (a five-year AD follow-up validation).
Results
Demographic and clinical characteristics. The demographics and clinical characteristics of the study 
participants were presented in Table 1. For the cross-sectional cohort, patients with AD had significantly higher 
mean age, lower level of education, and more frequent apolipoprotein E (APOE) ε4 allele and hypertension than 
CN individuals. In the longitudinal cohort, aMCI converters had significantly more frequent APOE ε4 alleles and 
lower baseline mini-mental state examination (MMSE) scores than aMCI non-converters. There were no signifi-
cant demographic differences between AD slow- and fast-decliners.
Subjects for classifier training Patients with aMCI Patients with AD
CN AD p-value Total
Non-
converters Converters p-value Total
Slow-
decliners Fast-decliners p-value
N 869 473 79 53 (67.1) 26 (32.9) 27 14 (51.9) 13 (48.1)
Age, y 65.4 (9.0) 73.0 (9.4) <0.001 69.7 (8.8) 69.1 (9.0) 70.9 (8.6) 0.410 70.4 (7.6) 72.0 (6.6) 68.8 (8.4) 0.276
Age of onset, y — 68.5 (10.7) — 67.1 (8.6) 66.3 (8.6) 68.5 (8.4) 0.308 67.2 (7.7) 68.0 (6.9) 66.4 (8.7) 0.595
Women 599 (68.9) 307 (64.9) 0.133 46 (58.2) 29 (54.7) 17 (65.4) 0.366 18 (66.7) 10 (71.4) 8 (61.5) 0.695
Education, y 11.7 (4.9) 9.4 (5.3) <0.001 12.1 (4.6) 12.1 (4.4) 12.1 (5.0) 0.971 10.3 (5.1) 9.5 (6.2) 11.2 (3.6) 0.392
APOE ε4 present* 135 (22.8) 180 (55.6) <0.001 29 (39.2) 15 (29.4) 14 (60.9) 0.010 4 (66.7) 2 (50.0) 2 (100.0) 0.467
MMSE 28.5 (2.0) 18.2 (5.5) <0.001 26.4 (2.4) 27.0 (1.9) 25.4 (3.0) 0.015 21.4 (3.1) 21.1 (3.0) 21.7 (3.3) 0.616
Vascular risk factors
 DM 178 (20.5) 112 (23.7) 0.174 35 (44.3) 26 (49.1) 9 (34.6) 0.225 6 (22.2) 5 (35.7) 1 (7.7) 0.165
 Hypertension 260 (29.9) 206 (43.6) <0.001 31 (39.2) 21 (39.6) 10 (38.5) 0.921 14 (51.9) 8 (57.1) 6 (46.2) 0.568
 Hyperlipidemia 238 (27.4) 90 (19.0) 0.001 25 (31.6) 19 (35.8) 6 (23.1) 0.251 6 (22.2) 3 (21.4) 3 (23.1) 1.000
 History of IHD 110 (12.7) 43 (9.1) 0.049 17 (21.5) 9 (17.0) 8 (30.8) 0.161 2 (7.4) 1 (7.1) 1 (7.7) 1.000
 History of stroke 32 (3.7) 26 (5.5) 0.118 2 (2.5) 2 (3.8) 0 (0.0) 0.316 1 (3.7) 1 (7.1) 0 (0.0) —
Table 1. Demographic and clinical characteristics of the study participants. Values are mean (SD) or N (%). 
Statistical analyses were performed with Chi-square, Fisher’s exact or Student’s t-tests. *APOE genotyping 
was performed in 916 (68.3%) of the 1,342 subjects for classifier training; 74 (93.7%) of the 79 patients with 
aMCI; and 6 (22.2%) of the 27 patients with AD, respectively. Abbreviations: N = number; SD = standard 
deviation; CN = cognitively normal; AD = Alzheimer’s disease; aMCI = amnestic mild cognitive impairment; 
APOE = apolipoprotein E; MMSE = mini-mental state examination; DM = diabetes mellitus; IHD = ischemic 
heart disease.
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Group classification performance. We assessed classification performance using the 10-fold 
cross-validation procedure on the cross-sectional cohort. Our classifier showed accuracy, sensitivity and spec-
ificity values of 91.1%, 83.5%, and 95.2%, respectively, for discriminating AD patients from CN individuals. 
Figure 1A shows the discriminating regions of our classification on the atlas surface meshes. The colored regions 
in the figure were determined by the amount of contribution of each vertex to classification. That is, the visualiza-
tion of the axis that is maximally separating two groups in the linear discriminant analysis (LDA) space represents 
the contribution of the component to classification4. The entorhinal cortex and precuneus were the most discrim-
inative for AD classification, and the lateral temporal lobe and the prefrontal cortex were also discriminative. In 
addition, we performed the validation of our classification method with the previously proposed method, support 
vector machine. The discriminative regions for both classifiers were consistent with each other (Supplementary 
Figure 1).
Figure 1. Discriminating features of our classification. (A) The discriminating regions of our classification on 
the atlas surface meshes and (B) The discriminative pattern of each patient with aMCI and AD. Color intensities 
in the figure represent discriminative power in AD classification. aMCI = amnestic mild cognitive impairment; 
AD = Alzheimer’s disease.
www.nature.com/scientificreports/
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Validation of clinical progression in patients with aMCI and AD. Subjects from the longitudinal 
aMCI and AD cohorts were used to validate the proposed cortical atrophy pattern analysis. Figure 1B visualizes 
the cortical atrophy patterns of each AD and aMCI patient group over time. The y-axis in the figure represents 
the AD-specific cortical atrophy similarity measure compared with the representative cross-sectional AD patient 
cohort used to develop the classifier. In patients with aMCI, non-converters showed no significant discriminative 
pattern, while converters demonstrated significant discriminative patterns in the inferior parietal lobule at base-
line and in the prefrontal, temporal cortices, and inferior parietal lobule at first year follow-up visit, respectively. 
From the baseline to the third year follow-up visits, AD slow-decliners showed discriminative patterns defined 
around the prefrontal and temporal cortices, while AD fast-decliners demonstrated significant discriminative 
patterns in the most of prefrontal, inferior parietal, and temporal cortices.
There were significant differences in the AD-specific atrophy similarity measure at both baseline and first year 
follow-up visits between aMCI converters and non-converters (Fig. 2A). Specifically, converters showed signif-
icantly greater increases of the AD-specific atrophy similarity measure over time than did non-converters on a 
mixed effects model (β = 3.6, standard error [SE] = 1.6, p = 0.027). In patients with AD, furthermore, there were 
significant differences between fast- and slow-decliners in the AD-specific atrophy similarity measure at baseline, 
first year, and third year follow-up visits (Fig. 2B). AD fast-decliners also showed significantly greater increases of 
the AD-specific atrophy similarity measure than did slow-decliners on a mixed effects model (β = 2.9, SE = 1.3, 
p = 0.029). Specific details regarding the AD-specific atrophy similarity and neuropsychological performance of 
both of the longitudinal cohorts by group status can be found in Supplementary Table 1.
Table 2 shows mixed effects models examining how worsening in neuropsychological test performance over 
time was related to AD-specific atrophy similarity in patients with aMCI and AD. Significant AD-specific atrophy 
similarity-by-time interactions were obtained for most neuropsychological tests in the two longitudinal cohorts 
from baseline to year one or three. Specifically, we found AD-specific atrophy similarity by time interactions in 
both groups for language function, Seoul Neuropsychological Screening Battery-Dementia version (SNSB-D) 
total score, MMSE, and Clinical Dementia Rating sum of boxes (CDR-SB), while there were significant inter-
actions for only the AD group in attention, memory, frontal/executive function, and Clinical Dementia Rating 
(CDR).
Discussion
In this study, we developed and validated an AD-specific atrophy similarity measure as a novel MRI-based bio-
marker to provide prospective AD risk prediction on an individual subject level. We found that the AD-specific 
atrophy similarity measure showed promising results at an individual-level, where it not only supported the 
early prediction of AD, but also enabled the discrimination of brain and clinical trajectories in patients with 
AD dementia. The AD-specific atrophy similarity measure, based on cortical thickness analyses we recently 
Figure 2. Comparisons of the AD-specific atrophy similarity at baseline and follow-up years: (A) non-
converters vs. converters in patients with aMCI and (B) slow- and fast-decliners in patients with AD. Mixed 
effects models of the worsening in AD-specific atrophy similarity over time between the classified groups by 
clinical progression in patients with aMCI and AD showed significant differences between the groups (p = 0.027 
in aMCI cohort and p = 0.029 in AD cohort). aMCI = amnestic mild cognitive impairment; AD = Alzheimer’s 
disease.
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developed, was derived from a probabilistic statistical classification model. Our method demonstrated high clas-
sification performance in the prediction of AD trajectories and in accurately distinguishing AD patients from 
normal controls, supporting the discriminative power of our method in both prognosis and diagnosis.
Our conclusion that the AD-specific atrophy similarity measure contributes to prediction of prognosis along 
the AD continuum is supported by the following observations: (1) in patients with aMCI, converters showed 
higher AD-specific atrophy similarity than non-converters with increasing scores at baseline and one-year 
follow-up visits; (2) in patients with AD dementia, fast-decliners also revealed higher AD-specific atrophy sim-
ilarity than slow-decliners at all visits over a three-year follow-up. More specifically, our findings of the discrim-
inative patterns in patients with aMCI converters and AD fast-decliners were consistent with previous literature 
findings of predicting AD prognosis which presented changes in the lateral temporal and inferior parietal cortices 
were related with AD progression21,22. Furthermore, significant inverse relationships between the AD-specific 
atrophy similarity measure and cognitive performance over time were observed in patients with aMCI and AD. 
Our study therefore provides new insight into both the prediction of aMCI to AD conversion and the prediction 
of accelerated clinical decline in AD dementia. Further follow-up will allow us to examine whether baseline atro-
phy similarity measurements can predict the specific time-to-conversion at the individual subject level.
While there have been several recent neuroimaging studies on the prediction of conversion from aMCI to AD 
dementia, most have exhibited limited prediction accuracy and small sample sizes23–26. We investigated the use 
of the AD-specific atrophy similarity measure as a means to obtain a sensitive and specific biomarker of AD-like 
spatial patterns of cortical thinning, and of conversion from aMCI to AD within a large cohort. Some recent stud-
ies using a cortical thickness-based clustering method demonstrated that AD patients with a parietal-dominant 
atrophy pattern showed poor performance in neuropsychological tests as well as aggressive rates of progres-
sion6,18. In comparison, a strength of our study is that different rates of disease progression were investigated 
by the AD-specific atrophy similarity measure on an individual subject level, and not using cluster or group 
analyses. Specially, our method has increased statistical power since the AD-specific atrophy similarity measure 
was derived using machine learning over a large neuroimaging cohort of AD and CN participants. In addition, 
the current study limited MRI data collection to one scanner with the same scan parameters across waves of data 
collection, strengthening the consistency of our data and results.
However, some limitations should be considered when interpreting the results. First, pathologic confirmation 
was not performed in the present study participants. Considering the discrepancy in diagnosis for AD between 
clinical and neuropathological data27, and a certain portion of clinically diagnosed AD patients may show nega-
tive amyloid positron emission tomography scan28, we cannot exclude the possibility that our classification meth-
ods might have been altered by AD-mimicking patients. However, this argument is mitigated to some degree by 
our previous studies showing that about 90% of clinically diagnosed AD had positive amyloid positron emission 
tomography scan29,30. Second, our classification scheme is based on the assumption that the cortical thickness 
data could be separated into two categories, such as CN and AD. As some neural network-based methods would 
be able to handle non-linearity of the feature data, future studies could employ these recently developed deep 
learning approaches. Third, there is no consensus regarding the time window during which conversion from 
aMCI to AD must be evaluated, or regarding specific cut-points for defining fast and slow decline in patients 
with AD. Fourth, two longitudinal cohorts for validation of the AD-specific atrophy similarity had relatively 
small sample size. Fifth, the proposed classification and AD-specific atrophy similarity measure methods are 
solely based on the cortical thickness data, and the clinical risk factors and neuropsychological score data were 
not used. As future works, it would be promising if we could see how those factors can affect the classification 
performance and atrophy pattern analysis results. Finally, since other classification methods were using various 
AD-specific atrophy 
similarity by time
Patients with aMCI Patients with AD
Estimate SE p-value Estimate SE p-value
Neuropsychological tests
 Attention −0.018 0.030 0.563 −0.121 0.041 0.003
 Language −0.112 0.036 0.030 −0.344 0.078 <0.001
 Visuospatial −0.032 0.120 0.791 −0.180 0.186 0.338
 Memory −0.370 0.276 0.186 −0.438 0.213 0.044
 Frontal/executive −0.041 0.168 0.809 −0.542 0.169 0.002
 SNSB-D total −0.107 0.350 0.048 −1.604 0.464 0.001
MMSE −0.064 0.035 0.024 −0.263 0.077 0.001
CDR 0.003 0.003 0.390 0.027 0.010 0.013
CDR-SB 0.042 0.020 0.003 0.145 0.044 0.002
Table 2. Mixed effects models of worsening in the neuropsychological test performances over time by AD-
specific atrophy similarity in patients with aMCI and AD. Linear mixed effects model were performed using 
AD-specific atrophy similarity, time, and the interaction term between AD-specific atrophy similarity and 
time (AD-specific atrophy similarity by time) as fixed effects and patient as random effect. AD-specific atrophy 
similarity was computed using w-score based on age and education. Abbreviations: aMCI = amnestic mild 
cognitive impairment; AD = Alzheimer’s disease; SE = standard error; SNSB-D = Seoul Neuropsychological 
Screening Battery-Dementia version; MMSE = mini-mental state examination; CDR = Clinical Dementia 
Rating; CDR-SB = Clinical Dementia Rating sum of boxes.
www.nature.com/scientificreports/
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types of feature data with different dataset, it is difficult to compare the classification performance of our method 
with other methods, directly.
In conclusion, we have developed an AD-specific atrophy similarity measure as a novel MRI-based biomarker. 
This method provides an innovative approach for enabling the prediction of dementia risk, and for evaluating 
trajectories along the AD continuum on an individual subject level. Furthermore, while further research is still 
necessary to validate and further develop the AD-specific similarity measure in other populations, this method 
will facilitate risk stratification not only for prevention trials but also for personalized therapy.
Methods
Study participants. Cross-sectional cohort for development of the AD classifier. A total of 536 patients with 
probable AD dementia and 912 CN individuals who underwent high-resolution 3T brain MRI with 3D volu-
metric imaging and detailed neuropsychological testing were recruited from the Memory Disorders Clinic of 
the Samsung Medical Center (from June 2006 to June 2012). The patients with probable AD dementia fulfilled 
the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and 
Related Disorders Association (NINCDS-ADRDA) criteria31. CN individuals had no history of neurologic or 
psychiatric disorders, and had normal cognitive function determined using neuropsychological tests (above the 
16th percentile for age- and education-matched norms).
We excluded 63 AD patients with any of the following conditions: missing education data (N = 9); unreliable 
cortical thickness measurements due to head motion, blurring of the MRI, inadequate registration to a stand-
ardized stereotaxic space, misclassification of tissue type, or inexact surface extraction (N = 31); or severe white 
matter hyperintensities (WMH) defined as deep WMH ≥ 25 mm and periventricular WMH ≥ 10 mm (N = 40). 
Since study participants could have more than one exclusion condition, the final sample size of AD patients was 
473. In addition, out of 912 CN individuals, we excluded 22 participants with incomplete demographic data. 
From the remaining 890 participants, we excluded 21 participants with unreliable analyses of cortical thickness, 
yielding 869 CN individuals for analysis in this study.
Laboratory tests were conducted in all participants to rule out other causes of dementia, and included com-
plete blood counts, vitamin B12 and folate levels, a metabolite profile, thyroid function tests, and syphilis serology. 
Participants were also excluded if they had a cerebral, cerebellar, or brainstem infarction, hemorrhage, tumors, 
hydrocephalus, or severe head trauma.
Longitudinal cohort for validation of the AD-specific atrophy similarity measure. A total of 79 aMCI patients 
were retrospectively recruited from the Memory Disorders Clinic of the Samsung Medical Center (from August 
2007 to December 2010). These aMCI patients had completed at least their first year follow-up visit with the same 
interview and neuropsychological tests as their baseline evaluation, had undergone high-resolution 3T brain 
MRI with 3D volumetric imaging, and did not have any critical missing data. Patients were diagnosed with aMCI 
using the Petersen criteria32 with the following modifications, which have been previously described in detail33: 
(1) a subjective cognitive complaint by the patient or his/her caregiver; (2) normal Activities of Daily Living 
(ADL) score determined clinically and with the instrumental ADL scale; (3) an objective cognitive decline below 
the 16th percentile (−1.0 standard deviation [SD]) of age- and education-matched norms in at least one of four 
cognitive domains (language, visuospatial, memory or frontal-executive function) on neuropsychological tests; 
and (4) absence of dementia. Patients with aMCI were grouped as non-converters (N = 53) if they were diag-
nosed with aMCI at baseline and remained so during their first year of follow-up, and as converters if they were 
diagnosed with aMCI at baseline and diagnosed with AD during their first year of follow-up, without reversion 
to aMCI or CN (N = 26).
We also included 36 patients with AD who participated in the prospective, five-year longitudinal Alzheimer’s 
Disease and Positron Emission Tomography (ADAPET) study, and were recruited from March 2006 to December 
2006. The patients fit the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition34 
and the NINCDS-ADRDA criteria for probable AD31. The enrolled patients were eligible if they had early-stage 
dementia with a CDR score of 0.5 or 1, were cooperative candidates for this longitudinal study, and had a car-
egiver. None had a family history suggestive of an autosomal dominant disease. Of 36 patients with AD, 27 
patients who completed the third year of evaluation were enrolled in the current study. The assessment procedure 
of the participants has been described in detail elsewhere35,36. Patients with AD were grouped as fast-decliners 
(N = 13) if their CDR-SB score increased more than five points during the three year follow-up; otherwise, they 
were labeled as slow-decliners (N = 14).
Standard protocol approvals, registrations, and patient consents. We obtained written informed consent from 
each patient. This study was approved by the Institutional Review Board at the Samsung Medical Center. In addi-
tion, all methods were carried out in accordance with the approved guidelines.
Neuropsychological tests. All participants underwent a standardized neuropsychological battery, the Seoul 
Neuropsychological Screening Battery (SNSB), which is described in detail elsewhere37. The SNSB consists of tests 
for verbal and visual memory, attention, language, praxis, four elements of Gerstmann syndrome, visuospatial 
function, frontal/executive function, the MMSE, the CDR, and the CDR-SB. From the SNSB results, we calculated 
the SNSB-D score in attention, language, visuospatial, memory, and frontal/executive domains, as previously 
described37,38.
Image acquisition and preprocessing. 3D T1-weighted Turbo Field Echo MRI images were acquired from all par-
ticipants in this study using the Philips 3T Achieva MRI scanner with the same imaging parameters (sagittal slice 
www.nature.com/scientificreports/
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thickness 1.0 mm, over contiguous slice acquisition with 50% overlap; no gap; repetition time 9.9 ms; echo time 
4.6 ms; flip angle 8°; and matrix size 240 × 240 reconstructed to 480 × 480 over a 240 mm field of view).
For each subject, we performed image preprocessing using FreeSurfer 5.1.0 (Athinoula A. Martinos Center at 
the Massachusetts General Hospital, Harvard Medical School; http://surfer.nmr.mgh.harvard.edu/). Figure 3A 
shows the overview of our image preprocessing method. We first constructed the outer and inner cortical surface 
meshes from the MR volume of each subject. The two meshes are isomorphic with the same vertices and connec-
tivity because the outer surface is constructed by deforming the inner surface. In order to establish inter-subject 
correspondence, we resampled each subject’s cortical surface to 40,962 vertices for each hemisphere using the 
previously proposed method4.
For removing noise in the cortical thickness data, we employed the manifold harmonic transform (MHT) to 
map the cortical thickness from the surface onto the frequency domain39,40. The MHT regarded high frequency 
components of the transformed cortical thickness data as noise, and then discarded those components4. It enables 
us to remove noise and reduce the dimensionality of the cortical thickness data by filtering out high frequency 
components.
Cortical atrophy pattern analysis. We analyzed the cortical atrophy pattern for each subject based on the pre-
processed cortical thickness data. Specifically, cortical atrophy patterns were quantified using Inbrain®, a Korea 
Food and Drug Administration (KFDA)-cleared software and a registered trademark of MIDAS Information 
Technology Co., Ltd., which performs fully-automated image analysis of brain structures. The proposed method 
consists of two steps: training a group classifier (Fig. 3B) and computing an AD-specific pattern similarity 
(Fig. 3C). The noise-filtered cortical thickness data was converted to w-score adjusting for age and education level 
in order to minimize the effects of them on cortical thickness. For classifier training, we used w-scores as feature 
vectors and employed principal component analysis (PCA) and LDA41. Specifically, we reduced the dimensional-
ity of feature vectors with PCA, and found coordinate axes which maximally separated different groups with LDA. 
Given feature vectors as input, the classifier was trained by performing PCA and LDA in sequence. We calculated 
the PCA dimension following the methods of our previous paper4.
After training the group classifier, the AD-specific pattern similarity measure was then calculated on an 
individual subject basis. As shown in Figure 3C, the noise-filtered cortical thickness data of an individual sub-
ject was transformed to PCA space using the pre-trained PCA axes. Similarly, the feature vector in PCA space 
was also mapped onto a single point in LDA space using the pre-trained LDA matrix. Finally, we measured the 
AD-specific similarity of the cortical atrophy pattern for an individual subject based on the distance between 
each subject’s mapped point and the mean value of the AD group in LDA space. A higher AD-specific atrophy 
similarity measure indicates that a subject’s brain atrophy pattern is more similar to the representative pattern of 
the AD group (Fig. 4).
In order to evaluate group classification performance, we performed a 10-fold cross-validation procedure. We 
randomly partitioned total participants into two sets of 90% for training and 10% for test. After training the clas-
sifier with training data, we assessed the accuracy, sensitivity and specificity of each classification with test data. 
In addition, we validated the AD-specific atrophy similarity measure in two longitudinal cohorts of patients with 
Figure 3. Overview of the proposed method. (A) Image preprocessing; (B) Group classifier training; and  
(C) AD-specific pattern similarity computation. AD = Alzheimer’s disease.
www.nature.com/scientificreports/
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aMCI and AD. Specifically, we applied the longitudinal pipelines of FreeSurfer for our longitudinal cohort data. 
As the FreeSurfer longitudinal pipeline is designed to be unbiased to any particular time, we did not initialize it 
with information from a specific time point. Instead, a template was created using information from all availa-
ble time points. This template can be regarded as an initial guess for segmentation of brain regions and surface 
reconstruction. The longitudinal pipeline consists of three steps42: cross-sectional image processing, individual 
template construction, and longitudinal alignment. According to the template surface, the FreeSurfer-provided 
fsaverage was used, and the smoothing process was applied similarly to the previous work4. We manually checked 
the results of every step and corrected any error that occurred during the surface construction step.
Statistical analyses. Continuous variables were presented as means ± SD and were compared using Student’s 
t-test. Categorical variables were compared using the Chi-square test or Fisher’s exact test. To examine how lon-
gitudinal changes in neuropsychological test performance over time were associated with AD-specific atrophy 
similarity in patients with aMCI and AD, we performed linear mixed effects modeling within each cohort using 
AD-specific atrophy similarity, time, and the interaction term between AD-specific atrophy similarity and time 
(AD-specific atrophy similarity by time) as fixed effects and patient as a random effect. In addition, to determine 
whether there are significant differences in the AD-specific similarity over time between the groups by clinical 
progression in patients with MCI and AD, we also performed linear mixed effects modeling within each cohort 
using group, time, and the interaction term between group and time (group by time) as fixed effects and patient as 
a random effect. Statistical significance was set at p < 0.05 in two-tailed tests. Statistical analyses were performed 
using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA).
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